1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €112.77 (+122.29%). The median is €120.21 (+136.96%).
| Buy |
7 |
| Hold |
4 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -14.22M | 710.86% |
| EBITDA | -12.71M | 637.37% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €136.9M |
Number of shares | 2.75M |
52-week high/low | €206.08 - €6.23 |
| Dividends | No |
Beta | 3.36 |
P/E ratio | -1.42 |
PEG ratio | -0.02 |
P/B ratio | 1.68 |
P/S ratio | 0.00 |
Company profile
| Name | Spruce Biosciences |
| CEO | Javier Szwarcberg |
| Headquarters | South San Francisco,
ca USA |
| Sector | Materials |
| Industry | Chemicals |
| Employees | 22 |
Discover assets
Shareholders of Spruce Biosciences also invest in the following assets
